Activating SRC mutation in a subset of advanced human colon cancers
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers. c-Src has been found to be highly activated in colon cancers, particularly in those metastatic to the liver. Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region. We report here the identification of a truncating mutation in SRC at codon 531 in 12% of cases of advanced human colon cancer tested and demonstrate that the mutation is activating, transforming, tumorigenic and promotes metastasis. These results provide, for the first time, genetic evidence that activating SRC mutations may have a role in the malignant progression of human colon cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundIdentification of a transformation-specific antigen induced by an avian sarcoma virus
BRUGGE, J. S., & ERIKSON, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 888
Kmiecik, T. E., & Shalloway, D. (1987) · Cell · doi:10.1016/0092-8674(87)90756-2 · Cited by 623
Tyr 527 Is Phosphorylated in pp60 c- src : Implications for Regulation
Cooper, J. A., Gould, K. L., Cartwright, C. A., & Hunter, T. (1986) · Science · doi:10.1126/science.2420005 · Cited by 540 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundThe when and how of Src regulation
Cooper, J. A., & Howell, B. (1993) · Cell · doi:10.1016/0092-8674(93)90634-3 · Cited by 533
Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src
Piwnica-Worms, H., Saunders, K. B., Roberts, T. M., Smith, A. E., & Cheng, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90757-4 · Cited by 520
Cell Transformation by the Viral src Oncogene
Jove, R., & Hanafusa, H. (1987) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.03.110187.000335 · Cited by 401
Self-citationIncrease in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Cited by
Items 101–200 of 507
Differential expression of Aquaporin 8 in human colonic epithelial cells and colorectal tumors
Fischer, H., Stenling, R., Rubio, C., & Lindblom, A. (2001) · BMC Physiology · doi:10.1186/1472-6793-1-1 · Cited by 100
“The majority of colorectal tumors, however, are sporadic, and studies in sporadic tumors have revealed other genes of importance in colorectal tumor development, e.g. K-Ras [2], TGFβ [3], E-cadherin [4], SRC [5] and the PPARγ [6].”
BackgroundTargeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Nagathihalli, N. S., Smith, J. J., Revetta, F. L., Washington, M. K., & Merchant, N. B. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1212 · Cited by 103
Laird, A., Li, G., Moss, K. G., Blake, R. A., Broome, M. A., Cherrington, J. M., & Mendel, D. B. (2003) · PubMed · Cited by 117
Chou, M. T., Wang, J., & Fujita, D. J. (2002) · BMC Biochemistry · doi:10.1186/1471-2091-3-32 · Cited by 98
Self-citationRitchie, S. A., Pasha, M. K., Batten, D. J. P., Sharma, R. K., Olson, D. J. H., Ross, A. R. S., & Bonham, K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg246 · Cited by 97
“For example, activation and/or overexpression of pp60c±src has been observed in many colon (5±8) as well as breast (9±12) carcinomas, and activating mutations in the SRC gene have been detected in a limited number of advanced colon tumors (13).”
BackgroundInvasive Prostate Carcinoma Driven by c-Src and Androgen Receptor Synergy
Cai, H., Babić, I., Wei, X. X., Huang, J., & Witte, O. N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1605 · Cited by 100
Ye, Y. N., Liu, E. S. L., Shin, V. Y., Wu, W. K. K., Luo, J. C., & Cho, C. H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058321 · Cited by 104
“%) of highly advanced colon tumors has verified an important role for c-Src in the progression of colorectal cancer (Irby et al., 1999).”
BackgroundTargeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer
Egloff, A. M., & Grandis, J. R. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.03.008 · Cited by 101
Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis
González, L., Agulló-Ortuño, M. T., García-Martínez, J. M., Calcabrini, A., Gamallo, C., Palacios, J., Aranda, A., & Martín-Pérez, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601570200 · Cited by 93
Schneditz, G., Elias, J. E., Pagano, E., Cader, M. Z., Saveljeva, S., Long, K. R., Mukhopadhyay, S., Arasteh, J. M., Lawley, T. D., Dougan, G., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aau9048 · Cited by 96
Elliott, B. E., Hung, W., Boag, A. H., & Tuck, A. B. (2002) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y02-010 · Cited by 102
Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Gaykalova, D. A., Mambo, E., Choudhary, A. K., Houghton, J., Buddavarapu, K., Sanford, T., Darden, W., Adai, A. T., Hadd, A. G., Latham, G. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093102 · Cited by 99
“48 SRC colon, liver, lung, breast none Signal transduction pathways [86,87] targeted exon”
BackgroundThe src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases
Shah, N. H., Amacher, J. F., Nocka, L. M., & Kuriyan, J. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1495173 · Cited by 99
“A small subset of patients with advanced human colon cancers contain a truncating mutation in their c-Src gene immediately adjacent to the regulatory C-terminal phosphorylation site at Tyr 527 (Figure 6(A)) (Irby et al. 1999).”
BackgroundSchenone, S., Bruno, O., Ranise, A., Bondavalli, F., Brullo, C., Fossa, P., Mosti, L., Menozzi, G., Carraro, F., Naldini, A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.013 · Cited by 98
Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?
Šušva, M., Missbach, M., & Green, J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01567-4 · Cited by 95
Kinases as targets in the treatment of solid tumors
Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K. M., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.011 · Cited by 98
The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy
Lieu, C., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 86
Read, R. D., Bach, E. A., & Cagan, R. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6676-6689.2004 · Cited by 85
“C-terminal domain to inhibit Src kinase activity (31).”
Src in endosomal membranes promotes exosome secretion and tumor progression
Hikita, T., Kuwahara, A., Watanabe, R., Miyata, M., & Oneyama, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-39882-z · Cited by 85
Paronetto, M. P., Farini, D., Sammarco, I., Maturo, G., Vespasiani, G., Geremia, R., Rossi, P., & Sette, C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63212-9 · Cited by 85
“Remarkably, mutation and/or deletion of this carboxyterminal phosphotyrosine residue in Src kinases have been detected in human colon cancers.(15) On the other hand, the strong tumor suppressor DOC-2/DAB2 directly interacts with the SH3 domain of Src and inhibits the activity of the kinase and prostate cell proliferat…”
BackgroundDebruyne, P. R., Bruyneel, E. A., Karaguni, I.-M., Li, X., Flatau, G., Müller, O., Zimber, A., Gespach, C. P., & Mareel, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205729 · Cited by 85
“Furthermore, mutations at Tyr530, hampering the negative autoregulatory feedback of the Src kinase activity, are found in advanced colorectal cancers (Irby et al., 1999).”
BackgroundKinG: a database of protein kinases in genomes
Krupa, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkh019 · Cited by 83
A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK
Mitchell, P. J., Sara, E., & Crompton, M. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203775 · Cited by 83
“More recently, activating mutations in src have been found in a subset of advanced human colon carcinomas (Irby et al., 1999).”
Backgroundc-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
Belli, S., Esposito, D., Servetto, A., Pesapane, A., Formisano, L., & Bianco, R. (2020) · Cancers · doi:10.3390/cancers12061489 · Cited by 89
“Although a truncated c-Src C-terminal region that exhibits constitutive catalytic activity was detected in small subsets of colon and endometrial cancers [12,13], the genetic mutations of c-Src represent a rare event in cancer development and progression.”
BackgroundPoh, A. R., Love, C. G., Masson, F., Preaudet, A., Tsui, C., Whitehead, L. W., Monard, S. P., Khakham, Y., Burstroem, L., Lessène, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.006 · Cited by 86
“Cancer Cell 31, 563–575, April 10, 2017 ª 2017 Elsevier Inc. 563 advanced human colon colorectal cancer (CRC) (Irby et al., 1999).”
BackgroundRegulation of both apoptosis and cell survival by the v-Src oncoprotein
Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W. C., Frame, M. C., & Wyke, J. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400700 · Cited by 82
“Many tumours, particularly those of the colon, have high levels of c-Src expression(63,64) and a few metastatic colon tumours have mutated c-Src which could be important in tumour progression.(65) We showed previously how v-Src induces transformation via effects on cell growth and behaviour.”
BackgroundRivat, C., Le Floch, N., Sabbah, M., Teyrol, I., Redeuilh, G., Bruyneel, E., Mareel, M., Matrisian, L. M., Crawford, H. C., Gespach, C., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0132fje · Cited by 81
“Activating SRC mutation at codon 531 was found in 12% of cases of advanced human colon cancer and was associated with cellular transformation and metastatic potential (24).”
BackgroundIdentification of Src transformation fingerprint in human colon cancer
Malek, R. L., Irby, R. B., Guo, Q. M., Lee, K., Wong, S., He, M., Tsai, J., Frank, B., Liu, E. T., Quackenbush, J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205900 · Cited by 81
“Other activating mutations have been described that increase Src kinase activity and transforming potential, including a stop codon mutation at amino acid 531 (Irby et al., 1999; Jove et al., 1989; Kato et al., 1986; Levy et al., 1986).”
BackgroundMethodSelf-citationFunctional implication of the interaction between EGF receptor and C-SRC
Leu, T., & Maa, M.-C. (2003) · Frontiers in bioscience · doi:10.2741/980 · Cited by 87
“Interestingly, a mutant c-src encoding a truncated human cSrc that ends with Tyr-530 (analogous to Tyr-527 in chicken c-Src) has been identified in colon carcinoma with high metastatic potential (15).”
BackgroundThe pp60c‐Src inhibitor PP1 is non‐competitive against ATP
Karni, R., Mizrachy‐Schwartz, S., Sklan, E. H., Gazit, A., Livnah, O., & Levitzki, A. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00069-3 · Cited by 87
Jones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80
“It was also recently reported that an activating mutation of c-Src, at tyrosine 527 in the carboxy-terminal regulatory region, occurred in a sub-set of advanced, metastatic colon cancers (Irby et al, 1999).”
BackgroundOsteopontin and colon cancer progression
Yeatman, T. J., & Chambers, A. F. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022502805474 · Cited by 80
“edu scribed include activating alterations of oncogenes such as Ras [3] and Src [4] as well as mutational inactivation of tu-”
BackgroundSelf-citationAn Update on Src Family of Nonreceptor Tyrosine Kinases Biology
Espada, J., & Martín-Pérez, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.009 · Cited by 87
Coexpression of IGF-1R and c-Src Proteins in Human Pancreatic Ductal Adenocarcinoma
Hakam, A., Fang, Q., Karl, R. C., & Coppola, D. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1026122421369 · Cited by 78
Self-citationThe genetic pathogenesis of colorectal cancer
Lynch, J. P., & Hoops, T. C. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00029-1 · Cited by 98
“Activating mutations described in a subset of advanced colon cancers [233].”
Backgroundc‐Src drives intestinal regeneration and transformation
Cordero, J. B., Ridgway, R. A., Valeri, N., Nixon, C., Frame, M. C., Muller, W. J., Vidal, M., & Sansom, O. J. (2014) · The EMBO Journal · doi:10.1002/embj.201387454 · Cited by 77
“There is rationale for a driver role for Src within CRC, and putative Src activating mutations were reported specifically within CRC, with amplification found in up to 20% of the advanced human CRC tumours (Irby et al, 1999; The Cancer Genome Atlas Network, 2012; www.cbioportal.org/public-portal).”
BackgroundArdini, E., Agresti, R., Tagliabue, E., Greco, M., Aiello, P., Yang, L., Ménard, S., & Sap, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203869 · Cited by 77
“The mutation enhances c-Src kinase activity, and is transforming, tumorigenic, and promotes metastasis (Irby et al., 1999), providing powerful evidence that selection for SFK activation contributes to tumor progression.”
BackgroundInfluentialBridge, R. S., Bridge, J. A., Neff, J. R., Naumann, S., Althof, P. A., & Bruch, L. A. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.019026 · Cited by 76
The Src signaling pathway: a potential target in melanoma and other malignancies
Homsi, J., Cubitt, C. L., & DAUD, A. I. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.1.91 · Cited by 83
“Src mutations with a tumorigenic and metastasis, promoting truncation mutation at codon 531 occur in 12% of cases of advanced human colon cancer shown by sequence analysis [47].”
BackgroundCooperative Roles of Fyn and Cortactin in Cell Migration of Metastatic Murine Melanoma
Huang, J., Asawa, T., Takato, T., & Sakai, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308213200 · Cited by 73
APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review
Liang, T.-J., Wang, H.-X., Zheng, Y.-Y., Cao, Y.-Q., Wu, X., Zhou, X., & Dong, S.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17576 · Cited by 70
Sirvent, A., Bénistant, C., Pannequin, J., Veracini, L., Simon, V, Bourgaux, J.-F., Hollande, F., Cruzalegui, F., & Roche, S. (2010) · Oncogene · doi:10.1038/onc.2009.450 · Cited by 69
“In contrast to Ras, Src activation by mutation is a rare event, suggesting the existence of alternative mechanisms for oncogenesis (Irby et al., 1999).”
BackgroundSrc activation in melanoma and Src inhibitors as therapeutic agents in melanoma
Homsi, J., Cubitt, C. L., Zhang, S., Munster, P. N., Yu, H., Sullivan, D. M., Jove, R., Messina, J. L., & Daud, A. I. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e328304974c · Cited by 67
Self-citationMicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression
Oneyama, C., Morii, E., Okuzaki, D., Takahashi, Y., Ikeda, J., Wakabayashi, N., Akamatsu, H., Tsujimoto, M., Nishida, T., Aozasa, K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.367 · Cited by 70
“The c-src gene is rarely mutated, but c-Src function is nonetheless upregulated in some cancer cells (Irby et al., 1999; Irby and Yeatman, 2000).”
BackgroundThe Tumor Suppressor Functions of p27kip1 Include Control of the Mesenchymal/Amoeboid Transition
Berton, S., Belletti, B., Wolf, K., Canzonieri, V., Lovat, F., Vecchione, A. M., Colombatti, A., Friedl, P., & Baldassarre, G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00144-09 · Cited by 71
Ritchie, S. A., Boyd, M., Wong, J. W. H., & Bonham, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.847 · Cited by 68
Is Src the key to understanding metastasis and developing new treatments for colon cancer?
Chen, J. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1141 · Cited by 67
Dickinson, S. I., Zhang, H. Q., Yuan, Z. Q., Cheng, J. Q., Karl, R. C., Jove, R., & Coppola, D. (2003) · Human Pathology · doi:10.1053/s0046-8177(03)00354-x · Cited by 73
Self-citationTargeting Phosphatases and Kinases: How to Checkmate Cancer
Turdo, A., D’Accardo, C., Glaviano, A., Porcelli, G., Colarossi, C., Colarossi, L., Mare, M., Faldetta, N., Modica, C., Pistone, G., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.690306 · Cited by 74
Cancers of the Colon and Rectum: Identical or Fraternal Twins?
Hong, T. S., Clark, J. W., & Haigis, K. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0315 · Cited by 66
Activated Src Oncogene Phosphorylates R-Ras and Suppresses Integrin Activity
Zou, J. X., Liu, Y., Pasquale, E. B., & Ruoslahti, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m103133200 · Cited by 65
Active Src Elevates the Expression of β-Catenin by Enhancement of Cap-Dependent Translation
Karni, R., Gus, Y., Dor, Y., Meyuhas, O., & Levitzki, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.12.5031-5039.2005 · Cited by 73
“We wanted to examine whether activated Src specifically affects the translation of HIF-1 or whether this effect is actually more general and affects other signaling proteins.”
BackgroundInfluentialLoza‐Coll, M., Rosen, K. V., Ladeda, V., & Filmus, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205388 · Cited by 73
“Irby et al. (1999) have reported that activating c-Src mutations can be found in a proportion of colorectal tumors, but these results have not been reproduced by others (Daigo et al., 1999; Laghi et al., 2001).”
ResultSawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64
Shore, S. K. (2003) · Frontiers in Bioscience · doi:10.2741/1138 · Cited by 65
Identification of Targets of c-Src Tyrosine Kinase by Chemical Complementation and Phosphoproteomics
Martinez-Ferrando, I., Chaerkady, R., Zhong, J., Molina, H., Jacob, H. K. C., Herbst, K. J., Rabbitts, B. M., Katju, V., Bose, R., Zhang, J., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015750 · Cited by 70
“However, v-Src forms are rarely found in human cells, even in cancer (6).”
BackgroundSarkar, T. R., Sharan, S., Wang, J., Pawar, S. A., Cantwell, C. A., Johnson, P. F., Morrison, D. K., Wang, J., & Sterneck, E. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05790-11 · Cited by 67
“Overexpression of a constitutively activated Src truncated at amino acid 531 (Src-531) (30) in MCF-10A cells resulted in the downregulation of endogenous C/EBP protein levels, whereas expression of the related protein C/EBP was not affected (Fig.”
BackgroundFocal adhesion kinase as a potential target in oncology
McLean, G. W., Avizienyte, E., & Frame, M. C. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.227 · Cited by 70
“Activating mutations in some tyrosine kinase genes, including c-src [46], are also associated with human malignancies [47]; however, no mutated forms of FAK have been described, although evidence does exist for both the overexpression of the FAK protein and increased dosage of the fak gene.”
BackgroundGriffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408550200 · Cited by 60
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Sirvent, A., Bénistant, C., & Roche, S. (2012) · Europe PMC (PubMed Central) · Cited by 78
Florio, A. D., Capurso, G., Milione, M., Panzuto, F., Geremia, R., Fave, G. D., & Sette, C. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01318 · Cited by 63
Chong, Y., Mulhern, T. D., Zhu, H., Fujita, D. J., Bjorge, J. D., Tantiongco, J.-P., Sotirellis, N., Lio, D. S. S., Scholz, G. M., & Cheng, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309865200 · Cited by 59
Self-citationKurata, H., Thant, A. A., Matsuo, S., Senga, T., Okazaki, K., Hotta, N., & Hamaguchi, M. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4738 · Cited by 61
Targeting Src signaling in metastatic bone disease
Araujo, J., & Logothetis, C. (2009) · International Journal of Cancer · doi:10.1002/ijc.23998 · Cited by 58
“Src mutations resulting in constitutive activation of the kinase domain of the protein have been found in a subset of human colon cancers.(28) However, it is thought that increased Src protein expression and/or kinase activity play a greater role in tumorogenesis than in mutations.”
BackgroundHaskell, M. D., Slack, J. K., Parsons, J. T., & Parsons, S. J. (2001) · Chemical Reviews · doi:10.1021/cr0002341 · Cited by 63
Novel regulation and function of Src tyrosine kinase
Ma, Y. C., & Huang, X. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8438-2 · Cited by 58
slambrouck, S. V., Grijelmo, C., Wever, O. D., Bruyneel, E. A., Emami, S., Gespach, C. P., & Steelant, W. F. A. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1501 · Cited by 74
“Increased expression and mutational activation of src has been reported in a subset of metastatic tumors (23), however, other mechanisms activating the src proto-oncogene including complex crosstalks with growth factor receptors and G-protein coupled receptors were also described (24,25).”
BackgroundIntegrin αvβ3 Controls Activity and Oncogenic Potential of Primed c-Src
Huveneers, S., van den Bout, I., Sonneveld, P., Sancho, A., Sonnenberg, A., & Danen, E. H. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3654 · Cited by 60
Restriction of Src Activity by Cullin-5
Laszlo, G. S., & Cooper, J. A. (2009) · Current Biology · doi:10.1016/j.cub.2008.12.007 · Cited by 57
“The mutants encode proteins SrcY529F (SrcYF), which lacks its C-terminal inhibitory Y529 and is fully active [7], and SrcQ530* (SrcQ*), which is partially phosphorylated at Y529 due to truncation of 6 C-terminal amino acids and is partly active [8].”
Srcasm Inhibits Fyn-Induced Cutaneous Carcinogenesis with Modulation of Notch1 and p53
Zhao, L., Li, W., Marshall, C. M., Griffin, T., Hanson, M., Hick, R. W., Dentchev, T., Williams, E. A., Werth, A. J., Miller, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2976 · Cited by 65
SRC transcriptional activation in a subset of human colon cancer cell lines
Dehm, S., Senger, M.-A., & Bonham, K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02354-1 · Cited by 54
Pathogenesis of colorectal cancer
de Leòn, M. P., & Percesepe, A. (2000) · Digestive and Liver Disease · doi:10.1016/s1590-8658(00)80361-8 · Cited by 71
Integrative Analysis of Cancer-Related Signaling Pathways
Keßler, T., Hache, H., & Wierling, C. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00124 · Cited by 57
“…(Gu et al., 2007), within coactivators of a signaling cascade (Björklund et al., 2007), components of the downstream signal transduction cascade (Irby et al., 1999; Bachman et al., 2004; Garnett and Marais, 2004; Carpten et al., 2007), or loss of function mutations of negative pathway…”
BackgroundImproving the prognosis for patients with glioblastoma: the rationale for targeting Src
de Groot, J., & Milano, V. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9916-2 · Cited by 59
Src, chemoresistance and epithelial to mesenchymal transition: are they related?
Shah, A. N., & Gallick, G. E. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801265d7 · Cited by 54
The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells
Purnell, P. R., Mack, P. C., Tepper, C. G., Evans, C. P., Green, T. P., Gumerlock, P. H., Lara, P. N., Gandara, D. R., Kung, H.-J., & Gautschi, O. P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819c78fb · Cited by 59
Parkin, A., Man, J., Timpson, P., & Pajic, M. (2019) · FEBS Journal · doi:10.1111/febs.15011 · Cited by 58
Targeting Tyrosine Kinases and Autophagy in Prostate Cancer
Kung, H.-J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0053-3 · Cited by 59
“This is likely due to the lack of frequent genetic mutations of this gene in human cancers, although rare mutation has been reported in colon cancer [42].”
Backgroundv-Src Generates a p53-Independent Apoptotic Signal
Webb, B. L., Jimenez, E., & Martin, G. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9271-9280.2000 · Cited by 52
“Mutational activation of Src occurs in some metastatic colon cancers (31), and overexpression or activation of Src is believed to contribute to the progression of breast and colon cancer (6).”
BackgroundSRC Signaling in Cancer and Tumor Microenvironment
Caner, A., Aşık, E., & Özpolat, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_4 · Cited by 52
Mon, N. N., Senga, T., & Ito, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5521 · Cited by 54
“In addition, genetic analysis has revealed an activating mutation in the C-terminus of Src in a subset of metastatic colon cancers (35).”
Qian, Y., Baisden, J. M., Zot, H. G., Van Winkle, W. B., & Flynn, D. C. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4795 · Cited by 51
Downregulation of Rap1GAP in Human Tumor Cells Alters Cell/Matrix and Cell/Cell Adhesion
Tsygankova, O. M., Ma, C., Tang, W., Korch, C. T., Feldman, M. D., Lv, Y., Brose, M. S., & Meinkoth, J. L. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01345-09 · Cited by 53
“The expression and activity of Src are increased in CRC with a trend toward increasing activity with disease progression (6, 12, 25, 44).”
BackgroundMutations leading to constitutive active gp130/JAK1/STAT3 pathway
Pilati, C., & Zucman‐Rossi, J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.010 · Cited by 53
Molecular targets and pathways involved in liver metastasis of colorectal cancer
Weidle, U. H., Birzele, F., & Krüger, A. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9732-3 · Cited by 53
Emaduddin, M., Bicknell, D. C., Bodmer, W. F., & Feller, S. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712176105 · Cited by 50
“Overexpression and hyperactivation of Src, not apparently associated with mutations in the Src gene, appears to be predominant in CRC, although occasional mutations have been reported (10, 11).”
BackgroundLiang, F.-P., Lin, C., Kuo, C., Chao, H., & Fu, S.-L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705877200 · Cited by 52
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer
Ischenko, I., Guba, M. O., Yezhelyev, M., Papyan, A., Schmid, G., Green, T., Fennell, M., Jauch, K., & Bruns, C. J. (2007) · Angiogenesis · doi:10.1007/s10456-007-9071-3 · Cited by 58
Src Redox Regulation: There Is More Than Meets the Eye
Chiarugi, P. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)14004-0 · Cited by 49
Wortmann, A., He, Y., Christensen, M. E., Linn, M., Lumley, J. W., Pollock, P. M., Waterhouse, N. J., & Hooper, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227462 · Cited by 49
Luo, F., Barrett, Y. C., Yang, Z., Camuso, A., McGlinchey, K., Wen, M.-L., Smykla, R. A., Fager, K., Wild, R., Palme, H., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0699-5 · Cited by 51
“activity than poorly metastatic cells; mutations in a critical carboxy-terminal tyrosine regulatory region of SRC lead to SRC activation and increased metastasis [11, 12].”
BackgroundRengifo-Cam, W., Konishi, A., Morishita, N., Matsuoka, H., Yamori, T., Nada, S., & Okada, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207041 · Cited by 49
“This mutation has been demonstrated to be activating, tumorigenic and to promote metastasis (Irby et al., 1999).”
BackgroundSammarco, I., Capurso, G., Coppola, L., Bonifazi, A. P., Cassetta, S., Fave, G. D., Carrara, A., Grassi, G. B., Rossi, P., Sette, C., et al. (2004) · International Journal of Colorectal Disease · doi:10.1007/s00384-004-0601-9 · Cited by 52
“mouse homologue of this alternative c-KIT product [29] and has shown that it is a strong activator of the Src-like kinases [30], a family of enzymes whose aberrant activation is associated with some human colon cancers [31, 32].”
BackgroundKrupa, A., & Srinivasan, N. (2002) · Genome biology · doi:10.1186/gb-2002-3-12-research0066 · Cited by 54
“Abnormal functioning of protein kinases has been implicated in a large number of human diseases and many of them have been identified as proto-oncogenes [5,6].”
BackgroundTorres‐Ayuso, P., Daza-Martín, M., Martín-Pérez, J., Ávila‐Flores, A., & Mérida, I. (2014) · Oncotarget · doi:10.18632/oncotarget.2344 · Cited by 54
“In contrast to viral oncoproteins, Src alone is insufficient to transform cells in vitro, and activating mutations of SFK are rarely observed in cancer [27, 28], suggesting further control by specific Src regulators that promote or restrain its tumorigenic properties [29, 30].”
BackgroundEichhorn, P. J. A., Creyghton, M. P., Wilhelmsen, K., van Dam, H., & Bernards, R. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030218 · Cited by 45
“However, overexpression of c-SRC by itself has only minor oncogenic potential [7] and mutations in c-SRC in cancer have only been found sporadically [8].”
Functional dissection of transformation by c‐Src and v‐Src
Oneyama, C., Hikita, T., Nada, S., & Okada, M. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01145.x · Cited by 50
The molecular rationale of Src inhibition in colorectal carcinomas
Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47
“A truncating mutation of c-src has been identified at codon 531 in 12% of advanced CRCs.(31) However, further studies found no mutations at the same codon among different populations, indicating that such alteration may be rare, ethnicspecific and probably not among the major tumorigenic mechanisms in CRC.”
BackgroundSu, B., Gao, L., Meng, F., Guo, L.-W., Rothschild, J. G., & Gelman, I. H. (2012) · Oncogene · doi:10.1038/onc.2012.218 · Cited by 47
“Although there are rare cases of breast and colon cancers expressing Src containing activating mutations akin to the so-called “viral Src signature” (66,67), Src likely drives oncogenic progression by virtue of being overexpressed or activated by upstream growth factor receptors (68,69).”
Metadata
- Authors
- Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- University of Calgary (CA)
- Corresponding author
- Yeatman, Timothy J.
- Venue
- Nature Genetics
- Published
- 1999-02
- Volume
- 21
- Issue
- 2
- Pages
- 187-190
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- DOI
- 10.1038/5971
- OpenAlex
- W1594706458
- Cited by
- 489
- References
- 28
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 2 · 2023: 11 · 2022: 1 · 2021: 5 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 19 · 2013: 12 · 2012: 21
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- National Institutes of Health (5k11ca065512-03)
- National Cancer Institute (R01CA055652, CA-55652, CA65512)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Src kinase, colon cancer, truncating mutations, non-receptor tyrosine kinase, oncogenic transformation, carcinogenesis, liver metastasis, malignant progression, Rous sarcoma virus
- MeSH terms
- Animals, Cell Line, Colonic Neoplasms, Humans, Liver Neoplasms, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Neoplasm Transplantation, Transfection, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Genes, src, Proto-Oncogene Proteins pp60(c-src), 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.